Company* |
Funding |
Amount |
Type# | Details (Date) |
| | ||||
Aastrom |
National Institute of Diabetes and Digestive and Kidney Diseases |
$0.416 |
Phase II SBIR grant |
The grant will be used to support use of the company's tissue repair cells in bone formation and vascularization (8/16) |
Acumen |
National Institute on Aging |
ND |
SBIR grant |
To develop a diagnostic to test levels of amyloid-beta-derived diffusible ligands from patients with Alzheimer's disease (8/11) |
Adenosine |
Department of Health and Human Services |
$2 |
Phase I/II SBIR grant |
The grant will support completion of Phase I and II trials of ATL-146e to prevent cardiac reperfusion injury (7/7) |
AdipoGenix |
National Institute of Diabetes and Digestive and Kidney Diseases |
ND |
Phase I SBIR grant |
For use in a collaboration with ChemDiv Inc. to further progress small molecules that target human fat tissue for treating obesity and Type II diabetes (6/23) |
Alnylam |
Michael J. Fox Foundation for Parkinson's Research |
ND |
Grant |
The grant will support work on the use of small interfering RNAs to silence alpha-synuclein, the overexpression of which has been linked to Parkinson's disease (8/15) |
Altor |
National Cancer Institute |
ND |
Phase I SBIR grant |
The grant will support development of Altor's processes for making therapeutic antibodies in transgenic lettuce (7/21) |
Artemis |
German government |
€1.3 |
Grant |
The grant will support work from Artemis and RiNA GmbH to develop methods to knock down human disease-related genes in the rat via RNA interference (7/19) |
Avant Immuno- |
National Institutes of Health |
$0.374 |
Subcontract from Harvard Medical School |
Avant got a portion of the $0.5M Harvard grant to develop a VitriLife formulation of its cholera vaccine CholeraGarde (7/18) |
BioVisioN AG* |
German Federal Ministry of Education and Research |
€0.56 (US$0.69) |
BioChancePLUS program grant |
BioVision will apply it Peptidomics technologies to analyze sub- strates and products of proteases in vivo (8/4) |
Blue Heron |
National Human Genome Research Institute |
ND |
Phase I SBIR grant |
The grant funds development of protein bead technology forstudying protein function (9/15) |
Blue Heron |
National Institute of General Medical Science and the NIAID |
ND |
Phase I SBIR grant |
The grant funds development of molecular biological tools to enable research on genes that are difficult to grow in bacteria (9/8) |
Bolder |
National Cancer Institute |
$0.122 |
Phase I SBIR grant |
To evaluate the company's long- acting gamma interferon analogue for treating ovarian cancer in animal models (8/12) |
CellCentric |
National Endowment for Science, Technology and the Arts (UK) |
£0.15 (US$0.27) |
Funding support |
The funding will be used to increase discovery capacity for epigenetic-related cancer targets and therapeutics (9/5) |
Ceragenix |
National Institutes of Health |
$1.2 |
Grant |
To study the role of the skin's barrier function as it relates to eczema vaccinatum, a potentially fatal complication of smallpox vaccination (8/17) |
ChemDiv Inc.* |
National Institutes of Health |
$9 |
Grant |
ChemDiv and research teams in New Mexico got the three-year grant to develop the New Mexico Molecular Library Screening Center (7/11) |
CODA |
National Institute of Allergy and Infectious Diseases |
$0.5 |
STTR grant |
CODA and the University of California at Irvine will use the grant to expand synthetic gene assembly and protein expression technologies (9/1) |
Crucell NV |
Dutch Ministry of Economic Affairs |
€2 (US$2.4) |
Senter grant |
The grant supports an effort to apply MAbstract technology to the discovery of antibodies to assist in the development of drugs against antibiotic-resistant bacteria (9/16) |
Crucell NV (the |
National Institutes of Health |
$19.2 |
Grant |
The funds will support development of adenovirus vector-based vaccines against HIV/AIDS; about $8M is earmarked for development of Crucell's AdVac technology (8/1) |
CureLab Inc.* |
National Institutes of Health |
ND |
Phase I SBIR grant |
The grant will support development of a vaccine against the influenza virus; CureLab said funding is expected to eventually total $7M (8/1) |
DCV |
National Cancer Institute |
$0.1 |
Grant |
For preclinical research on the company's dendritic-cell immuno- therapy in ovarian cancer (6/14) |
DermTech |
University of California |
$0.138 |
Discovery grant |
For research on a product for the non-invasive diagnosis of early stage melanoma (6/23) |
Elusys |
National Institute of Allergy and Infectious Diseases and the Department of Defense |
$5.4 |
Funding awards |
The funding will support development of Anthim, an antibody therapeutic for preventing and treating anthrax infection; $4.4M came from the NIAID and $1M from the DOD (8/3) |
Encore |
National Institute on Aging |
$0.75 |
Phase II SBIR grant |
To support work with the Oklahoma Medical Research Foundation on a drug candidate for amyotrophic lateral sclerosis and Huntington's disease (8/9) |
EntreMed |
Susan G. Komen Breast Cancer Foundation |
ND |
Grant |
Duke University got the grant to test EntreMed's Panzem (2ME2) in combination therapies for metastatic breast cancer (6/29) |
Galapagos NV |
Dutch government |
€2 (US$2.4) |
Senter grant |
The companies will work with the Netherlands Institute for Universiteit Amsterdam to develop treatments for acute spinal cord and peripheral nerve damage (9/14) |
Galapagos NV |
Dutch Ministry of Economic Affairs |
€1.2 (US$1.5) |
Grant |
To support a drug discovery program in arthritis that includes ZoBio BV, Pyxis Discovery BV and Leiden University (8/10) |
GeneGo Inc.* |
National Institute of General Medical Science |
ND |
Phase II SBIR grant |
To further develop the computational tool MetaDrug to improve the prediction of ADME and toxicology properties of novel small- molecule compounds (8/3) |
GeneGo Inc.* |
Department of Defense |
ND |
SBIR grant |
The grant will support development of a systems biology suite of tools for visualization and analysis of proteomic data (6/27) |
GeneGo Inc.* |
National Institute of General Medical Science |
ND |
Phase I SBIR grant |
The grant will support development of methodologies to reconstruct functional networks affected in common human diseases (6/13) |
Genencor |
Defense Advanced Research Projects Agency |
ND |
Grant |
To develop a process for the rapid manufacture of emergency pharmaceuticals to defend against biological agents (8/29) |
Gene Network |
National Heart, Lung and Blood Institute |
$0.138 |
Phase I SBIR grant |
The grant will be used to further the company's efforts in cardiac modeling and in silico safety testing (7/26) |
Genomic Profiling |
National Institute of Allergy and Infectious Diseases |
$4.1 |
Phase II SBIR grant |
Three-year grant to develop a testing platform for rapid and ultra- sensitive diagnosis of anthrax (8/12) |
Hana Biosciences |
National Institutes of Health |
$0.159 |
SBIR grant |
The grant supports preclinical studies of Talotrexin (PT-523) as part of chemotherapy regimens (8/8) |
Hyalose LLC* |
Oklahoma Center for Advancement of Science and Technology |
$0.227 |
Grant |
The grant will support development of hyaluronan-assisted targeting systems for drug delivery (7/18) |
Icoria Inc. |
Environmental Protection Agency and Duke University |
ND |
Contracts |
Icoria will provide microarray expression services related to environmental toxicants in each deal (9/8) |
Icoria Inc. |
National Institute |
$1.2 |
Phase II SBIR contract |
Funding will be used to discover biomarkers for drug-induced liver injury (8/29) |
ImaRx |
National Heart, Lung and Blood Institute |
$1.1 |
Phase II SBIR grant |
The grant supports development of targeted nanobubbles that can be used with ultrasound for NanoInvasive treatment of vascular clots (8/2) |
Immunicon |
National Institutes of Health |
$0.587 |
STTR grant |
To fund development of a strategy to monitor the effectiveness of cancer drugs in trials by examining a patient's blood for tumor cells and related materials (6/13) |
Inimex |
Bill and Melinda Gates Foundation and others |
$8.7 |
Grand Challenges in Global Health initiative grant |
Inimex is part of a consortium working to boost innate immunity to treat infectious diseases; the effort is led by the University of British Columbia (7/7) |
Inovio |
Department of Defense |
$1 |
Defense appropriation |
For development of its gene delivery electroporation technology for use in vaccines against infectious diseases (9/13) |
Ipsat |
Tekes; the Finnish National Technology Agency |
€3 (US$3.6) |
Funding support |
The funding will support product development through the proof-of-concept stage (6/16) |
Isis |
National Institute of Allergy and Infectious Diseases |
$4.9 |
Contract award |
The Ibis division of Isis will get up to $4.9M for continued development of its TIGER biosensor system for diagnosing infectious diseases and identifying and controlling hospital- associated infections (8/2) |
Isis |
U.S. government agencies |
$1.1 |
Subcontract from Science Applications International Corp. |
The Ibis division of Isis was awarded the contract, details of which were not disclosed (7/28) |
Isis |
Department of Homeland Security and other U.S. agencies |
$5 |
Subcontracts from Science Applications International Corp. |
The Ibis division of Isis will continue advancing development of the TIGER biosensor system for identifying infectious organisms (7/21) |
Lexicon |
The Texas Enterprise Fund |
$35 |
Contract award |
Lexicon will create a knockout mouse embryonic stem cell library containing 350,000 cell lines for the Texas Institute for Genomic Medicine (7/15) |
Medicure Inc. |
National Sciences and Engineering Research Council of Canada |
ND |
Collaborative Research and Development grant |
The grant will support development of drugs to reduce very- low-density lipoproteins (6/27) |
MeditechResearch |
Australian government |
A$2.98 (US$2.3) |
Commercial Ready Grant |
Three-year grant will support development of HyCAMP, a drug in Phase II trials for cancer (8/24) |
Metabolon |
National Institute of Mental Health |
ND |
Contract award |
To identify biomarkers occurring in women affected by premenstrual dysphoric disorder (6/16) |
Morphotek |
Defense Advanced Research Projects Agency |
$6.3 |
Challenge grant |
To apply its morphogenics technology to develop cell lines suit- able for the scaleable manufacturing of biologic-based anti-biowarfare therapies (9/15) |
MultiCell |
National Institute of Allergy and Infectious Diseases |
ND |
Grant |
The grant will support a pilot trial using its immunoglobulin therapeutic for treating Type I diabetes (9/14) |
MultiCell |
National Institutes of Health |
ND |
SBIR grant |
To create BioFactories that express a serine protease inhibitor that may be useful for treating sepsis (8/30) |
Nabi Bio- |
National Institute on Drug Abuse |
$4.1 |
Grant |
The grant will help fund development of NicVAX, a vaccine being developed to treat nicotine addiction and prevent smoking relapse (9/12) |
Nanogen Inc. |
National Institute of Allergy and Infectious Diseases |
$2.5 |
Grant |
The five-year grant is for development of a prototype integrated diagnostic system for identifying agents that cause sepsis and community-acquired pneumonia (8/1) |
Neurion |
National Institute of Mental Health |
$0.5 |
Phase I SBIR grant |
The grant will support development of drugs to treat anxiety focused on a GABA-A receptor subtype (6/2) |
Neurome |
National Institutes of Health and the Bill and Melinda Gates Foundation |
$3.9 |
Grand Challenges in Global Health Initiative grant |
Three-year program to develop a needle-free vaccine delivery system that will enable administration in any field setting (6/30) |
Neurome |
National Institutes of Health |
ND |
Phase I SBIR grant |
To develop and validate software to accelerate the graphical delineation of brain regions on digital images used to produce 3-D digital brain atlases (6/7) |
NexBio Inc.* |
National Institute of Allergy and Infectious Diseases |
$6 |
Phase II SBIR grant |
For further testing of the company's influenza candidate Fludase (DAS181), which is nearing clinical trials (8/8) |
OriGene |
National Human Genome Research Institute |
ND |
Phase I SBIR grant |
The grant will be used to validate OriGene's short-hairpin RNA Kinome collection (6/30) |
Osel Inc.* |
National Institute of Allergy and Infectious Diseases |
ND |
Grant |
The multiyear award will support development of an encapsulated MucoCept Lactobacillus strain for preventing bacterial vaginosis and HIV infection (6/9) |
Oxford BioMedica |
UK Motor Neurone Disease Association |
£0.35 (US$0.63) |
Research grant |
The grant will support preclinical evaluation of MoNuDin, a gene therapy treatment for amyotrophic lateral sclerosis (7/25) |
Progenics |
National Institute of Allergy and Infectious Diseases |
$10.1 |
Grant |
The 3.5-year grant will support research and clinical testing of the HIV drug PRO 140 (9/9) |
ProlX |
National Institutes of Health |
$1.2 |
SBIR grants |
ProlX got four grants to support development of the Trx-1 inhibitor PX-12 for cancer, and other drugs in the company's pipeline (8/18) |
Reaction |
National Institutes of Dental and Craniofacial Research |
$0.75 |
Phase II SBIR grant |
To apply its DiscoveryDot technology to the high-throughput screening of caspases and other proteases for drug discovery (8/9) |
RxKinetix Inc.* |
Bill & Melinda Gates Foundation and others |
ND |
Grand Challenges in Global Health initiative grant |
RxKinetix will use the grant to develop room-temperature, stable vaccines for measles and hepatitis B (6/30) |
Sanaria Inc.* |
National Institute of Allergy and Infectious Diseases |
$1 |
Phase II SBIR grant |
The first year of the grant will support development of its whole-parasite malaria vaccine; another $2M could be awarded over three years (6/20) |
SIGA |
National Institutes of Health |
$1 |
Funding support |
The funding will help support preclinical development of SIGA's oral anti-smallpox drug SIGA- 246, which is being developed with Saint Louis University (9/20) |
SIRS-Lab |
European Union |
ND |
6th Framework Program grant |
SIRS-Lab is the only non-academic member of the GenOSept project, which got funding to investigate the genetics of sepsis and septic shock (5/24) |
Solbec |
Edith Cowen University (Australia) |
ND |
Industry collaboration grant |
To identify a specific melanoma gene that may allow for development of diagnostic test (9/2) |
SGX |
National Institute of General Medical Sciences |
$48.5 |
Protein Structure Initiative award |
The NIH award provides five years of renewed funding for the New York Structural GenomiX Research Consortium; SGX will retain about half the funding, with the rest going to participating institutions (7/1) |
Thromgen Inc.* |
National Heart, Lung and Blood Institute |
$1.49 |
STTR Competing Continuation grant |
The grant will fund continued preclinical development of Thrombostatin for preventing blood clots following balloon angioplasty procedures (7/18) |
Tripos Inc. |
European Union |
€0.875 (US$1.1) |
6th Framework Program grant |
The grant will pay for seven research fellows from Europe to work at Tripos' UK unit for 18 months each over four years (6/7) |
United |
National Institutes of Health |
$17 |
Contract award |
The contract is expected to cover the full cost of the development and manufacture of a therapeutic vaccine for AIDS(7/5) |
Velcura |
National Institute on Aging |
$1.3 |
Phase II SBIR grant |
The grant is for proteomics-based drug discovery in human osteoblasts, for discovery of drugs that stimulate bone formation (7/12) |
Vesta |
National Institute of Diabetes and Digestive and Kidney Diseases |
ND |
Phase I SBIR grant |
The grant will support exploration of using adipose-derived adult stem cells as a therapeutic modality in liver disease (6/16) |
Vical Inc. |
Defense Advanced Research Projects Agency |
$0.5 |
Department of Defense award |
The award will fund feasibility studies for a new approach to rapidly manufacturing large quantities of DNA vaccines (9/22) |
Vical Inc. |
National Institute of Allergy and Infectious Diseases |
$2.9 |
Challenge grant |
Grant of up to $2.9M will be used support development of a DNA vaccine against naturally emerging or weaponized strains of avian influenza (9/15) |
Vical Inc. |
National Institute of Allergy and Infectious Diseases |
$12.1 |
Subcontract award from SAIC-Frederick Inc. |
Vical will provide multiple clinical lots of DNA vaccines against HIV for the Vaccine Research Center of the NIAID under the subcontract (6/16) |
VistaGen |
National Institute of Drug Abuse |
$0.197 |
Phase I SBIR grant |
The grant will support completion of preclinical efficacy studies of AV-101 for treating pain caused by various conditions (7/12) |
VistaGen |
High Q Foundation Inc. |
ND |
Funding support |
High Q will support VistaGen's preclinical studies of AV-101 for treating Huntington's disease (8/11) |
Zen-Bio Inc. |
National Institutes of Health |
$0.96 |
Phase II SBIR grant |
The two-year grant will support development and characterization of a human omental adipocyte cell system (9/21) |
Notes: | ||||
* Indicates a privately held company. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.